Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

The CAPTAIN trial compared the MRI-Guided TULSA Procedure™ to robotic radical prostatectomy for localized prostate cancer.

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

Joseph J. Busch, Jr., M.D. , a board-certified radiologist and Founder of the Busch Center in Alpharetta, GA, will give a presentation titled "Robotic Assisted MRI-Guided Transurethral Ultrasound ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Windsong Radiology Group President Dr. Raja Cheruvu became ...

When the PSA is elevated: for which men is a biopsy necessary to confirm or rule out suspected prostate cancer? In a retrospective study, scientists from the German Cancer Research Center (DKFZ) and ...

TORONTO, March 13, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...